Perfusion magnetic resonance imaging provides additional information as compared to anatomical imaging for decision-making in vestibular schwannoma  by Kleijwegt, M.C. et al.
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Objective:  The  added  value  of  perfusion  MRI  for decision-making  in vestibular  schwannoma  (VS)  patients
is unknown.  MRI  offers  two  perfusion  methods:  the ﬁrst  employing  contrast  agent  (dynamic  suscepti-
bility  contrast  (DSC)-MRI)  that  provides  information  on  cerebral  blood  volume  (CBV)  and  cerebral  blood
ﬂow (CBF),  the  second  by magnetic  labeling  of  blood  (arterial  spin  labeling  (ASL)-MRI),  providing  CBF-
images.  The  goal  of the  current  study  is  to  investigate  whether  DSC  and ASL perfusion  MRI  provides
complimentary  information  to  current  anatomical  imaging  in treatment  selection  process  of VS.
Methods:  Nine  patients  with  growing  VS with  extrameatal  diameter  >9 mm  were  included  (>2 mm/year
and  20%  volume  expansion/year)  and  one  patient with  23 mm  extrameatal  VS without  growth.  DSC and
ASL  perfusion  MRI  were  obtained  on  3 T  MRI. Perfusion  in  VS  was  scored  as  hyperintense,  hypointense
or  isointense  compared  to the  contralateral  region.
Results: Seven  patients  showed  hyperintense  signal  on DSC  and  ASL  sequences.  Three  patients  showed
iso-  or  hypointense  signal  on  at least one  perfusion  map  (1 patient  hypointense  on  both  DSC-MRI  and
ASL;  1 patient  isointense  on DSC-CBF;  1 patient  isointense  on  ASL).  All  patients  showed  enhancement  on
post-contrast  T1 anatomical  scan.
Conclusion:  Perfusion  MR  provides  additional  information  compared  to  anatomical  imaging  for  decision-
making  in  VS.
©  2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Vestibular schwannoma (VS) is a benign tumour that originates
rom the Schwann’s cell of the vestibular nerve, also known as the
ighth cranial nerve. The vestibular nerve is located in the cere-
ellopontine angle, the space between brainstem, cerebellum and
Abbreviations: AAO-HNS, American Academy of Otolaryngology-Head and Neck
urgery; ASL, arterial spin labeling; CA, contrast agent; CBF, cerebral blood ﬂow;
BV, cerebral blood volume; DSC, dynamic susceptibility contrast; EPI, echo planar
maging; FA, ﬂip angle; FOV, ﬁeld of view; Gd, gadolinium; MR,  magnetic resonance;
RI, magnetic resonance imaging; PCASL, pseudo-continuous arterial spin labeling;
F,  radiofrequency; rCBV, relative CBV; SNR, signal to noise ratio; TR, repetition time;
E, echo time; VS, vestibular schwannoma.
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temporal bone. Clinical complaints of VS generally consist of pro-
gressive unilateral hearing loss, vertigo and tinnitus. Tumours that
compress the brainstem give more general complaints, such as
headache, vision disorders and hypoesthesia of the face. Data from
Denmark shows an incidence of 19 VSs per 1 million people per
year, these data are seen as most complete because of the refer-
ral of all VSs from one country to one single clinic [1]. Diagnosis is
made by anatomical MRI  examination with or without the use of
contrast agent (CA).
Treatment options for VS are radiotherapy, surgery or obser-
vation with regularly magnetic resonance (MR) preferable with
the use of CA [2]. The choice for treatment is based both upon
tumour characteristics and patient characteristics. Such as tumour
size, growth rate, heterogeneity of the tumour and hearing loss.
The average tumour growth was  found to be 1–2 mm per year, but
varies [3]. Tumour size is both measured intra- and extrameatal
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. MR image of left sided vestibular schwannoma. Yellow dotted line is border
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EPI) sequence with echo time (TE) 30 ms,  ﬂip angle (FA) 90◦, wasetween intra- and extrameatal portion of the tumour. Size quantiﬁed as the largest
iameter measurable in the extrameatal portion (red line).
Fig. 1) [2]. Besides the tumour characteristics the patients prefer-
nces are important to decide for a treatment option. If tumour
ize is stable the frequency of MR  is decreased. The preferred
reatment option for intrameatal tumours is observation, although
ccasionally patients with functional hearing are operated to pre-
erve hearing [4]. Tumours localized extrameatal, which are larger
han 20 mm are generally spoken, advised to undergo treatment,
urgery or radiotherapy. Each treatment option has its speciﬁc ben-
ﬁts and side effects. The intention of radiotherapy is to freeze
he growth rate; but hearing loss and other cranial nerve pathol-
gy are common side effects [5]. Surgery usually results in hearing
oss at the operated side and can also affect the function of the
acial nerve [6]. In addition infection and haemorrhage are com-
on  complications. Patients with small or medium sized tumours
an experience a signiﬁcant decrease of their quality-of-life in each
reatment option with relatively small differences in quality-of-life
etween the treatment groups. It has been shown that not the treat-
ent modality itself, but the actual diagnosis of VS is the main cause
f decreasing quality-of-life in patients with VS [7,8]. Observation
s becoming the preferred initial treatment policy for VS [8,9]. In
rder to give an objective advice for patient speciﬁc treatment dur-
ng observation and to decrease side effects during radiotherapy or
urgery, it would be of clinical relevance if the growth rate could
e predicted.
For brain tumours it is known that vascularization can be mea-
ured using perfusion MRI  and that it can help in differentiation and
taging of brain tumours [10,11]. A tumour with a volume larger
han 2 mm3 is dependent on angiogenesis for growth, since the
umour growth critically depends on inﬂux of oxygen and nutri-
nts [12,13]. Perfusion MRI  has been used for early detection and
taging of many different tumour types, such as lung cancer and
liomas, although its added value for VS is yet unknown [14,15].
MRI  perfusion can be performed by two approaches, one with
nd the other without the use of CA, i.e. dynamic susceptibility con-
rast (DSC) MRI  and arterial spin labeling (ASL). DSC relies on the
ntravenous injection of a CA and serial MRI  measurement of sig-
al loss during the passage of the bolus through the tissue, using
2 or T2* weighted sequences. Using this technique, cerebral blood
olume (CBV) and cerebral blood ﬂow (CBF) can be calculated. ASL Radiology Open 3 (2016) 127–133
is a non-invasive perfusion MRI  method for quantitatively measur-
ing cerebral perfusion, by employing blood itself as an endogenous
tracer via inversion of longitudinal magnetization [16]. A difﬁculty
in the depiction of perfusion of VS lies in the magnetic ﬁeld inhomo-
geneities near the temporal bone, which could especially affect the
measurements of the intrameatal portion of the VS. Such concerns
on the imaging quality are probably the reason for the absence of
perfusion MRI  in many imaging protocols of VS patients. Only a few
studies show examples of perfusion MRI  in VS, and these studies
are limited to single subject examples [11,17].
The goal of the current study is to investigate the additional
value of the different perfusion MRI  methods to provide informa-
tion on the vascularization in VS.
2. Material and methods
2.1. Patients
The Leiden University Medical Center is a tertiary referral
centre for VS-patients in the Netherlands. Every other week all
new patients with VS are being (multidisciplinary) discussed, and
patient characteristics are documented in a database. From this
database ten patients were selected to be included in this study,
based upon the growth rate. Growth was assessed on two consecu-
tive MRI’s, where the extrameatal component was measured using
the American Academy of Otolaryngology-Head and Neck Surgery
(AAO-HNS) criteria (Fig. 1) [2]. This means that in the axial plan on a
T1 gadolinium-enhanced sequence the largest diameter was mea-
sured in anterior-posterior and medial-lateral dimension. Patients
with a growth rate larger than 2 mm/year and a volume increase of
more than 20% per year were included following literature proce-
dures [18,19]. A further inclusion criteria was that the extrameatal
diameter of the VS needed to be larger than 9 mm;  this to guarantee
good depiction even when taking the relatively coarse resolution
of perfusion MRI  sequences into account. Patients with neuroﬁbro-
matosis type 2 were excluded. The clinical state of the patients on
follow-up was documented.
The internal ethical review board of the Leiden University Med-
ical Center approved the study and all subjects provided written
informed consent.
2.2. MR  protocol
All experiments were performed on a clinical 3 T MRI  scanner
(Achieva 3 T, Philips Healthcare, Best, The Netherlands) equipped
with software to enable ASL imaging. Pseudo-continuous label-
ing was performed with a labeling duration of 1650 ms  (1650 RF
pulses of 0.5 ms  duration). ASL imaging was  performed in combina-
tion with background suppression, which consisted of a saturation
pulse immediately before labeling and inversion pulses at 1680
and 2830 ms  after the saturation pulse [20]. This leads to opti-
mal  background suppression for the ﬁrst acquired slice, whereas
the background signal in the other slices will gradually increase
due to T1-recovery. Imaging was performed with single-shot echo
planar imaging (EPI) in combination with parallel imaging (SENSE
factor 2.5). In total 17 slices of 5 mm slice thickness were acquired
in ascending fashion with an in-plane resolution of 3 × 3 mm2 (TE of
14 ms,  TR of 3.9 s). Imaging started 1525 ms  after labeling stopped.
The total scan was  4 min  (Table 1).
For DSC-MRI a single-shot spin-echo echo planar imaging (SE-used to cover an imaging volume of 13 slices for 96 s at a temporal
resolution of 1.64 s 15 mL  of gadolinium-based CA (Dotarem, Guer-
bet, France) was injected at a rate of 5 mL/sec followed by a chaser
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Table  1
Summary of acquisition parameters for ASL perfusion imaging.
Acquisition parameter ASL
Labeling PCASL
Labeling duration 1650 ms
Background suppression 1680 & 2830 ms
Pulse sequence Single shot EPI
TR 3.9 s
Voxel-size 3 × 3 × 5 mm
Slices 17
Slice thickness 5 mm
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Table 3
Patient characteristics.
Number 9
Mean age (years) 62 (45–74)
Gender male 6
female 3
Mean max. diameter 1 st MR mm 13.4
range mm 9.0–19.5
Mean max. diameter 2nd MR mm 15.9
range mm 12.2–22.4
Mean time between MR’s months 7.6
Mean volume 1st MR cm3 1.47
range cm3 0.72–3.42
Mean volume 2nd MR cm3 2.2
range cm3 0.97–4.84
Mean growth mm/yr 4.1
range mm/yr 2.3-7.0
.0Total scan time 4 min
f 25 mL  saline, also injected at 5 mL/sec [21,22]. A pre-bolus of 8 mL
A was given 5 min  before dynamic imaging (see Table 2).
.3. Post processing and statistical analysis
The label images of the ASL-sequence were subtracted from
he control images and averaging over the repeated measurements
as performed. No further quantiﬁcation was performed, since this
tudy employed a qualitative comparison of VS perfusion compared
o a contralateral region in the same slice. With vendor supplied
oftware (Philips Healthcare, Best, The Netherlands) the DSC-data
ere analysed. This was done by converting the MRI-signal changes
n time to R2(t) curves which were considered to reﬂect concen-
ration time curves by assuming linearity:
R2(t) = {−In(S(t)/S(0))}/TE
TE is the echo time, S(0) baseline signal intensity and S(t) MRI
ignal intensity as a function of time. From these concentration-
ime curves relative CBV and CBF-maps were reconstructed using
tandard tracer kinetic theory [23].
.4. MR  perfusion characteristics
Tumours where rated using a three point scale; hyperintense,
sointense and hypointense as compared to the contralateral side.
sing OsiriX© v5.5.2 32 bit, images of DSC-CBF, DSC-CBV and ASL-
BF sequences where registered with the T1 post contrast sequence
or accurate co-localization of hemodynamic and anatomical infor-
ation. This resulted in 4 MR  images per patient: T1 post contrast,
SC-CBF, DSC-CBV and ASL-CBF. These images where reviewed by a
adiologist to deﬁne whether the tumour was hyperintense, isoin-
ense or hypointense compared to contralateral side.
able 2
ummary of acquisition parameters for DSC perfusion imaging.
Acquisition parameter DSC
Pulse sequence SE-EPI
TR 1.6 s
TE  30 ms
Flip angle 90◦
Preload Gd- based contrast agent dose 8 mL  dose
Slices 13
Slice thickness 5 mm
Slice gap 0.5 mm
Voxel-size 2.5 × 2.5 × 4.5 mm
FOV 240 mm
IV  catheter gauge 18 gauge
Injection rate 5 mL/s
Total acquisition time 96 s
ote: TR = repetition time, TE = echo time, FOV = ﬁeld of view.volume/yr (%) 53.3
range volume/yr (%) 24.0–120
3. Results
3.1. Patients
Ten patients were included in this study (Table 3). Nine
patients with an unilateral fast growing (≥2 mm/year) extrameatal
vestibular schwannoma, ≥9 mm in diameter (axial measured) were
included. The VS of one patients showed minimal growth after the
perfusion MRI, although the patient did full ﬁll the inclusion criteria
of a growth of more than >2 mm per year based upon 2 consecu-
tives MRI’s. However, looking back at the consecutives MR’s it was
deemed debatable by a second observer whether this VS grew actu-
ally more than 2 mm and having a volume increase of 20% per year.
As of poor image quality the caudal part of the tumour was  over-
estimated for the second MRI. Therefore this patient was  excluded
for further analyses for fast growing tumours. Since the perfusion
MRI  of this patient was made, the results were analysed and dis-
cussed as an (single-subject) example of a slow growing tumour.
This patient was categorized as having a stable unilateral vestibular
schwannoma of 24 mm.
In Table 3 characteristics of all patients are shown. The mean
maximum diameter was  15.9 mm and the mean growth rate was
4.1 mm per year, the stable patient was  excluded from this mean.
3.2. Tumour characteristics
In Table 4 data regarding size, volume and growth are given for
every patient.3.3. MRI characteristics
In Table 5 the results are shown for perfusion MRI. Perfusion was
rated on a three-point intensity scale, hyperintense, isointense and
Table 4
Tumour characteristics.
Patient max  diameter (mm) Volume(cm3) growth (%/yr) growth (mm/yr)
1* 23.5 8.00 12.0 1.0
2  12.5 1.04 120.0 7.0
3  12.0 0.93 48.0 4.0
4  12.5 1.33 36.0 4.0
5  10.9 0.87 24.0 2.6
6  9.0 0.72 36.0 2.8
7  10.9 0.80 60.0 3.6
8  19.5 2.79 84.0 5.8
9  15.1 1.33 24.0 2.3
10  18.6 3.42 48.0 4.8
Note: *stable patient.
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Fig. 2. Imaging examples of 4 patients, from left to right: T1 post contrast, DSC-CBF, DSC-CBV and ASL-CBF. From top to bottom: patient 1, 2, 5, and 9. Red circle indicates
the  region-of-interest in the vestibular schwannoma (VS); yellow circle is the contralateral reference area. Arrows indicates the VS. (For interpretation of the references to
colour  in this ﬁgure legend, the reader is referred to the web  version of this article.)
a–d  shows the result of patient 1, on the posterior border there is hyperintensity visible (
e–h  shows the results of patient 2. All perfusion images where hyperintense. i–l patien
patient 9. DSC-CBF is isointense, DSC-CBV and ASL-CBF where hyperintense.
Table 5
MRI  characteristics.
Patient DSC-CBF DSC-CBV ASL-CBF T1 post contrast
1* hypointense hypointense hypointense hyperintense
2  hyperintense hyperintense hyperintense hyperintense
3  hyperintense hyperintense hyperintense hyperintense
4  hyperintense hyperintense hyperintense hyperintense
5  hyperintense hyperintense isointense hyperintense
6  hyperintense hyperintense hyperintense hyperintense
7  hyperintense hyperintense hyperintense hyperintense
8  hyperintense hyperintense hyperintense hyperintense
9  isointense hyperintense hyperintense hyperintense
10  hyperintense hyperintense hyperintense hyperintense
N
C
l
h
Fote: DSC-CBF = Dynamic susceptibility contrast—cerebral blood ﬂow, DSC-
BV = dynamic susceptibility contrast- cerebral blood volume, AS-CBF = arterial spin
abeling—cerebral blood ﬂow, * stable patient.ypointense as compared to a mirror location contralaterally. In
ig. 2 example images are shown for 4 patients.asterisk b-c), which is indicative for a vessel. All perfusion images are hypointense.
t 5. Both the DSC perfusion images are hyperintense. ASL-CBF is isointense. m–p
Seven patients showed on all the MR  perfusion scans hyper-
intense signal. The stable patient showed hypointense signal for
all modalities. One patient showed hyperintense signal in de DSC-
CBF and DSC-CBV sequences, but isointense signal in the ASL-CBF
sequence. Finally, one patient showed isointense signal in the DSC-
CBF sequences and hyperintense signal in the DSC-CBV and ASL-CBF
sequences. All patients had an enhancement on post-contrast T1
anatomical scan (Table 5).
Fig. 2a–d shows the results of the patient with slowly growing
VS. All perfusion images were hypointense. The T1 post contrast
was used for navigation purposes and showed hyperintense sig-
nal intensity as compared to the contralateral mirror-location.
Images 2b and 2c show hyperintense signal on the posterior border,
which is indicative for a vessel as conﬁrmed on the post contrast
T1 sequence. Fig. 2e–h shows the results of patient 2. All perfu-
sion images showed hyperintense signal. On the T1 post contrast
the tumour is cystic, in the perfusion images this cystic area is
hypointense. Fig. 2i–l gives an overview of the result of patient 5.
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oth the DSC perfusion images are hyperintense at the posterior
order with cerebellum. ASL-CBF is isointense. It should be stated
hat the full extend of the complete tumour was not included in the
mage data. Fig. 2m–p  resembles the result of patient 9. DSC-CBF is
sointense, DSC-CBV and ASL-CBF where hyperintense.
.4. Follow up data
For all patients included in this study the current clinical sta-
us on follow-up was reviewed. An overview of the information
s provided in Table 6. Since inclusion in the study the tumour
f patient 1 remained stable and no invasive treatment has been
erformed and is clinically still in the observation group. Patient 2
howed progressive growth and surgical removal was performed
ithin one month after perfusion MRI, histology conﬁrmed the
adiological diagnosis of VS. The residual VS after surgery was
table for 24 months after surgery. Patient 3 showed no growth
etween the perfusion MRI  and the most recent MRI  (interval 3
onths), but because of patient preferences, radiotherapy was per-
ormed. During follow up the tumour grew after radiotherapy;
his patient is still under observation. Patient 4 showed progres-
ive growth between the perfusion MRI  and the most recent
RI  (interval 3 months) and surgery was performed within one
onth after perfusion MRI. The histological examination showed
S. Patient 5 stayed under observation and is still stable, volumet-
ic growth could not be assessed because of incomplete imaging of
he tumour. Patient 6 had minimal growth, but because of invalidat-
ng vertigo and patients’ preferences surgery was  performed. Again
istopathology revealed VS. Patient 7 showed progressive growth
nd radiotherapy was performed because of patients’ preferences.
n the 6 months of radiological follow up the tumour stayed sta-
le. Patient 8 had also progressive growth and radiotherapy was
nitiated, currently there is no radiological follow up data. Patient
 had progressive growth, patient’s preferences results in continu-
ng observation. After 14 months, growth was still progressive and
urgery is currently planned. Patient 10 had progressive growth and
adiotherapy was performed. After radiotherapy, growth stayed
rogressive and because of hydrocephalus an intracranial drain
as placed. Currently, the patient is under observation whether
he post-radiotherapy oedema will diminish.
. Discussion
This study investigated whether it is possible to obtain
erfusion-weighted images of sufﬁcient quality in patients with
rowing VS. The main ﬁndings are that growing VS (≥9 mm
xtrameatal) are visible on perfusion weighted MR,  both ASL and
SC-MRI are suitable for assessing vascularization in VS, and that
hese techniques should be evaluated in future research for their
dded-value in the decision-making process of the treatment-
trategy in the individual VS patient.
Previous studies compared DSC perfusion images between var-
ous intracranial space occupying lesions [11,17]. VS was one of
he studied lesions, although it was limited to a single subject
xample. Hakyemez et al. showed that rCBV ratios of VS were
ower compared to meningiomas and metastases. Therefore they
oncluded that perfusion MRI  could be helpful for discriminating
chwannomas from meningiomas or other masses. Zimny et al. con-
rmed that low rCBV values could differentiate schwannoma from
eningioma. Although these studies are important by proving the
alue of perfusion MRI  in differentiating between different types of
ntracranial lesions, they lack the comparison of different perfusion
RI  techniques in the context of imaging VS, nor did they focus
n predicting future growth of VS. Table 4 shows that the three
atients with the lowest volume increase per year (i.e. patient 1, 5 Radiology Open 3 (2016) 127–133 131
and 9 with a volume expansion of 0%, 24%, 24% per year, respec-
tively), showed at least for one of the perfusion MR  approach iso- or
hypointense signal intensity compared to the contralateral region.
This in contradiction with the post-contrast T1-weighted images
that showed hyperintense signal in the VS for all patients. Although
our sample-size was  relatively small, these observations seem to
indicate that perfusion MRI  could show additional information as
compared to traditional MRI.
Several studies of intracranial masses compared ﬁndings
obtained by ASL and DSC perfusion MRI. Rau et al. investigated the
use of ASL and DSC imaging in the use of patients diagnosed with
high-grade gliomas. They found that relative CBF measurements
seemed to provide the best sensitivity and speciﬁcity to predict
tumour recurrence and survival times in these patients, there was
no difference between DSC and ASL [24]. Another study compared
ASL and DSC perfusion imaging for diagnosis in brain metastasis
and meningiomas showing comparable results for both perfusion
methods [25]. Furthermore, ASL and DSC might have similar pre-
dictive value for treatment outcome in brain metastases [26]. In
this study, Weber et al. found that after stereotactic radiosurgery
alteration of CBF was highly predictive for treatment outcome
[26]. Another comparative analysis of ASL and DSC found a close
correlation between ASL and DSC perfusion imaging in patients
with proven brain tumours [27]. These authors concluded that ASL
possesses the potential to be a non-invasive alternative for DSC
perfusion imaging particular in patients with renal failure; these
patients have a contraindication for CA.
The current study adds to the literature that also in the setting of
VS both perfusion MRI  approaches provide sufﬁcient image qual-
ity for assessing perfusion in VS and that in most patients both
approaches provided similar readings. Future clinical trials with a
higher number of included patients as well as with a longer follow-
up time would be necessary to proof superior behaviour of one
of the two  perfusion techniques. Furthermore, such a clinical trial
would be essential to proof whether inclusion of perfusion infor-
mation into the treatment selection process would improve clinical
outcome as compared to current standard clinical care. When com-
paring ASL with DSC, there are some important differences. ASL is
a completely non-invasive approach, but suffers from difﬁculty in
providing reliable measurements in low-CBF regions like the cere-
bral white matter, and it only provides information on CBF whereas
blood volume measurements have been found to be more informa-
tive for diagnosis and staging of brain tumours [28,29]. On  the other
hand, DSC is invasive because of the use of CA and its accuracy can
be affected due to leakage of CA, but it provides a more holistic view
on tumour hemodynamics by providing information on both CBV
and CBF. Leakage of CA violates the applied tracer kinetic model
since it is intrinsically a model for intravascular tracers. Further-
more, leakage of contrast agent leads to a signiﬁcant decrease in
T1 of the extravascular compartment, resulting in a signal increase,
which can lead to quantiﬁcation errors in the measurement of the
concentration of CA. By giving a pre-load of CA the T1-effect can
be minimized and this approach was adopted in the current study.
This study included one patient, which in retrospect did not meet
the inclusion criteria.
However, since the perfusion MRI  was already been made, the
data was  analysed and included in order to serve as a reference
to the data of patients with growing tumours. For future studies it
is worthwhile to investigate in a larger group of patients whether
growing and stable tumours differ signiﬁcantly in their perfusion
characteristics.
Limitations of this study are that the studied patient group is
very small, that perfusion information was  not used in treatment
decisions and that therefore no conclusion can be drawn on the
added value of perfusion MRI  on the decision making. Further-
more, we  employed a simplistic three-point scale to score perfusion
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Table 6
Follow up data.
Patient max diameter pre
perfusion MR  (mm)
max  diameter
Perfusion MR (mm)
Post-MR examination
growth (mm/yr)
Treatment histology Radiological follow up after
perfusion MR (Months)
Current state of the
tumour
1* 24.0 24.0 0.0 Observation – 13 Stable
2  16.0 16.8 2.1 Surgery VS 24 Stable residual
3  14.0 14.0 0.0 Radiotherapy 16 Growth
4  14.2 15.6 4.4 Surgery VS 12 Stable residual
5  12.2 12.2 0,0 Observation – 9 Stable
6  12.5 13.0 1.2 Surgery VS 16 Stable residual
7  13.6 19.2 5.6 Radiotherapy – 6 Stable
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[8  22.4 24.4 4.8 
9  16.6 18.6 2.1 
10  21.0 22 2.0 
mages. Such a simple scoring system reﬂects current approach in
he radiological clinic in which quantitative analysis is only rarely
erformed due to large intra- and intersubject variations in quan-
iﬁcation. This study was meant to provide initial evidence whether
erfusion MRI  might help in the clinical treatment strategy of
S patients and based on the result of the current study, further
esearch seems to be justiﬁed since perfusion MRI  provided sufﬁ-
ient image quality, provided insight into the heterogeneity of our
atients, which was informative over standard post-contrast MRI
hat in all patients showed signal enhancement independent of past
nd future growth rates.
In conclusion, this study showed that growing VS (≥9 mm
xtrameatal) are visible on perfusion-weighted MR,  that the two
echniques DSC and ASL provide similar imaging quality and that
uture research is needed to prove whether these techniques are of
mportance in the decision-making in VS-patients.
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